Melanoma subtypes demonstrate distinct PD-L1 expression profiles

Laboratory Investigation

Volumn 97, Issue 9, 2017, Pages 1063-1071

  Kaunitz, Genevieve J ^a   Cottrell, Tricia R ^a   Lilo, Mohammed ^a   Muthappan, Valliammai ^a   Esandrio, Jessica ^a   Berry, Sneha ^a   Xu, Haiying ^a   Ogurtsova, Aleksandra ^a   Anders, Robert A ^a   Fischer, Alexander H ^a   Kraft, Stefan ^b   Gerstenblith, Meg R ^c   Thompson, Cheryl L ^d   Honda, Kord ^c   Cuda, Jonathan D ^a   Eberhart, Charles G ^a   Handa, James T ^a   Lipson, Evan J ^a   Taube, Janis M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ACRAL MELANOMA; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRUCTURE; CHRONIC SUN DAMAGED MELANOMA; CLINICAL EVALUATION; COHORT ANALYSIS; CORRELATION ANALYSIS; CUTANEOUS MELANOMA; DESMOPLASTIC MELANOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT LENTIGO; MUCOSAL MELANOMA; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINDLE CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UVEA MELANOMA; CLASSIFICATION; GENE EXPRESSION PROFILING; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; SKIN; SKIN TUMOR; UVEA TUMOR;

ANTIGENS, CD274; COHORT STUDIES; GENE EXPRESSION PROFILING; HUMANS; MELANOMA; SKIN; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 85028511052     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2017.64     Document Type: Article

References (56)

1. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015;23:32-38.
2. Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 2016;34:4102-4109.
3. Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28:245-253.
4. Obeid JM, Erdag G, Smolkin ME, et al. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology 2016;5:e1235107.
5. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127-137.
6. Rodic N, Anders RA, Eshleman JR, et al. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunol Res 2015;3:110-115.
7. Danilova L, Wang H, Sunshine J, et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci USA 2016;113: E7769-E7777.
8. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: A synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011;24:879-897.
9. Busam KJ, Mujumdar U, Hummer AJ, et al. Cutaneous desmoplastic melanoma: Reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol 2004;28:1518-1525.
10. Jahn SW, Kashofer K, Halbwedl I, et al. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis. Mod Pathol 2015;28:895-903.
11. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.
12. Kamino H, Tam ST. Immunoperoxidase technique modified by counterstain with azure B as a diagnostic aid in evaluating heavily pigmented melanocytic neoplasms. J Cutan Pathol 1991;18:436-439.
13. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-5074.
14. Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 2016;1:52-63.
15. Yanik EL, Kaunitz GJ, Cottrell TR, et al. Association of HIV status with local immune response to anal squamous cell carcinoma: Implications for immunotherapy. JAMA Oncol 2017; doi: 10.1001/jamaoncol.2017.0115 (e-pub ahead of print).
16. Frydenlund N, Leone D, Yang S, et al. Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumorinfiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Mod Pathol 2017;30:357-369.
17. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793-800.
18. Karydis I, Chan PY, Wheater M, et al. Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology 2016;5:e1143997.
19. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366: 2443-2454.
20. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515: 568-571.
21. Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275-287.
22. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-918.
23. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-1117.
24. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-1030.
25. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372: 2521-2532.
26. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369: 134-144.
27. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.
28. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
29. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366: 2455-2465.
30. Yang W, Chen PW, Li H, et al. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci 2008;49:2518-2525.
31. Lee SJ, Lim HJ, Choi YH, et al. The clinical significance of tumorinfiltrating lymphocytes and microscopic satellites in acral melanoma in a Korean population. Ann Dermatol 2013;25:61-66.
32. Song H, Wu Y, Ren G, et al. Prognostic factors of oral mucosal melanoma: Histopathological analysis in a retrospective cohort of 82 cases. Histopathology 2015;67:548-556.
33. Thierauf J, Veit JA, Affolter A, et al. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res 2015;25:503-509.
34. Bonnelykke-Behrndtz ML, Steiniche T, Damsgaard TE, et al. MelanAnegative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin. Melanoma Res 2015;25:113-118.
35. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-1428.
36. Ock CY, Kim S, Keam B, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 2016;7:15901-15914.
37. Kim S, Koh J, Kim MY, et al. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum Pathol 2016;58:7-14.
38. Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128.
39. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520.
40. Shain AH, Garrido M, Botton T, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 2015;47:1194-1199.
41. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-263.
42. Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44: 1006-1014.
43. Furney SJ, Turajlic S, Stamp G, et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 2013;230:261-269.
44. Furney SJ, Turajlic S, Stamp G, et al. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res 2014;27:835-838.
45. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-2199.
46. Davoli T, Uno H, Wooten EC, et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017;355:6322.
47. Roh W, Chen PL, Reuben A, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 2017;9:379.
48. Sautes-Fridman C, Lawand M, Giraldo NA, et al. Tertiary lymphoid structures in cancers: Prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol 2016;7:407.
49. Eroglu Z, Kim DW, Johnson DB, et al. Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma [ASCO abstract 9011]. J Clin Oncol 2015;33(15 Suppl):9011.
50. Niederkorn JY. Ocular immune privilege and ocular melanoma: Parallel universes or immunological plagiarism Front Immunol 2012;3: 148.
51. D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis. J Clin Oncol 2017;35: 226-235.
52. Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 2016;122:3354-3362.
53. Cho J, Ahn S, Yoo KH, et al. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: Correlative analysis with PD-L1 immunohistochemistry. Invest New Drugs 2016;34:677-684.
54. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-567.
55. Kottschade LA, Mcwilliams RR, Markovic SN, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016;26:300-303.
56. Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016;122:3344-3353.